PerkinElmer opens Massachusetts facility

PerkinElmer (Waltham, Massachusetts), a technology and health sciences and photonics, celebrated the grand opening of its new corporate headquarters and technology center in Waltham, Massachusetts. The 115,000 square foot campus includes a state-of-the-art research and development facility for PerkinElmer's drug discovery, cellular science and diagnostics businesses. The event also marked PerkinElmer's 60th anniversary as a Massachusetts-based technology company.

"Today we celebrate PerkinElmer's proud history and bright future as an innovator as it continues to pioneer in the areas of predictive diagnostics, personalized medicine, and environmental monitoring," said Gregory L. Summe, CEO/chairman of PerkinElmer, Inc. Approximately 100 employees, customers, partners and special guests joined PerkinElmer to mark the occasion, which included a ribbon-cutting ceremony, facility tours and reception. The company currently employs nearly 600 people in Massachusetts, and has more than 8,500 employees worldwide.

Staff deficiency letter for CardioDynamics

CardioDynamics International (San Diego), a maker of impedance cardiography technology, reported that it received a NASDAQ staff deficiency letter from the listing qualifications department indicating that the company's common stock fails to comply with the minimum bid price requirement set forth in NASDAQ marketplace rule 4450(a)(5). The letter was issued in accordance with standard NASDAQ procedures because the company's common stock closed below $1 per share for 30 consecutive trading days.

The letter states that CardioDynamics will be afforded 180 calendar days, or until October 15, 2007, to regain compliance with the minimum bid requirement. To do so, the Company's stock must meet or exceed the $1 minimum bid price for at least 10 consecutive business days. If CardioDynamics is unable to achieve this requirement, NASDAQ will provide written notification to the company that its common stock is subject to delisting. At that time, CardioDynamics may appeal Nasdaq's determination to delist its common stock. Alternatively, the company may elect to apply to transfer its common stock from the NASDAQ Global Market, where it is currently listed, to the NASDAQ capital market if it satisfies all requirements, except for the bid price requirement, for initial inclusion in this market as set forth in Marketplace Rule 4310(c).